St John's Wort: Effect on CYP3A4 activity

Clinical Pharmacology and Therapeutics

Volumn 67, Issue 5, 2000, Pages 451-457

  Roby, Carol A ^a,b,c,d   Anderson, Gail D ^a,b,c,d   Kantor, Eric ^a,b,c,d   Dryer, Donna A ^a,b,c,d   Burstein, Aaron H ^a,b,c,d  

^a ST AGNES HOSPITAL   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME;

ADULT; ARTICLE; CLINICAL TRIAL; DEPRESSION; DRUG EFFECT; DRUG EXCRETION; ENZYME INDUCTION; HUMAN; HYDROCORTISONE URINE LEVEL; HYPERICUM PERFORATUM; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 0034076445     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1067/mcp.2000.106793     Document Type: Article

References (39)

1. 1. Eliason BC, Kruger J, Mark D, Rasmann DN. Dietary supplement users: demographics, product use, and medical system interaction. J Am Board Fam Pract 1997;10: 265-71.
2. 2. Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health Syst Pharm 1999;56:125-38.
3. 3. De Smet PA. Health risks of herbal remedies. Drug Saf 1995;13:81-93.
4. 4. Wong AH, Smith M, Boon HS. Herbal remedies in psychiatric practice. Arch Gen Psychiatry 1998;55:1033-44.
5. 5. Zink T, Chaffin J. Herbal "health" products: what family physicians need to know. Am Fam Physician 1998;58: 1133-40.
6. 6. Cupp MJ. Herbal remedies: adverse effects and drug interactions. Am Fam Physician 1999;59:1239-44.
7. 7. Heiligenstein E, Guenther G. Over-the-counter psychotropics: a review of melatonin, St John's Wort, valerian, and kava-kava. J Am Coll Health 1998;46:271-6.
8. 8. Josey ES, Tackett RL. St John's Wort: a new alternative for depression? Int J Clin Pharmacol Ther 1999;37:111-9.
9. 9. Hippius H. St John's Wort (hypericum perforatum): a herbal antidepressant. Curr Med Res Opin 1998;14:171-84.
10. 10. Landrum-Michalets E. Update: clinically significant cytochrome P450 drug interactions. Pharmacotherapy 1998;18:84-112.
11. 11. Smith G, Stubbins MJ, Harries LW, Wolf CR. Molecular genetics of the human cytochrome P450 monooxygenase superfamily. Xenobiotica 1998;28:1129-65.
12. 12. Smith DA, Abel SM, Hyland R, Jones BC. Human cytochrome P450's: selectivity and measurement in vivo. Xenobiotica 1998;28:1095-128.
13. 13. Burstein AH, Reiss WG, Kantor E, Anderson GD. Cytochrome P450 3A4 activity in premenopausal and postmenopausal women, based on 6-β-hydroxycortisol/ cortisol ratios. Pharmacotherapy 1998;18:1271-6.
14. 14. Ged C, Rouillon JM, Pichard L, Combalbert J, Bressot N, Bories P, et al. The increase in urinary excretion of 6-β-hydroxycortisol as a marker of human hepatic cytochrome P450IIIA induction. Br J Clin Pharmacol 1989;28:373-87.
15. 15. Bienvenu T, Rey E, Pons G, d'Athis P, Olive G. A simple non-invasive procedure for the investigation of cytochrome P-450 IIIA dependent enzymes in humans. Int J Clin Pharmacol Ther Toxicol 1991;29:441-5.
16. 16. Rost KL, Mansmann U, Roots I. Urinary 6-β-hydroxycortisol and D-glucaric acid excretion rates are not affected by lansoprazole treatment. Int J Clin Pharmacol Ther 1997;35:14-8.
17. 17. Ohnhaus EE, Breckenridge AM, Park BK. Urinary excretion of 6-β-hydroxycortisol and the time course measurement of enzyme induction in man. Eur J Clin Pharmacol 1989;36:39-46.
18. 18. Dolara P, Lodovici M, Salvadori M. Urinary 6-β-hydroxycortisol and paracetamol metabolites as a probe for assessing oxidation and conjugation of chemicals in humans. Pharm Res 1987;19:261-73.
19. 19. Saenger P. 6-β-Hydroxycortisol in random urine samples as an indicator of enzyme induction. Clin Pharmacol Ther 1983;34:818-21.
20. 20. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK. Urinary excretion of 6-β-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clin Pharmacol Ther 1998;63: 617-22.
21. 21. St John's wort. United States Pharmacopeia and National Formulary 24/19. Rockville (MD): United States Pharmacopeia; 2000. p. 2509-10.
22. 22. Roots I, Holbe R, Hovermann W, Nigam S, Heinemeyer G, Hildebrandt AG. Quantitative determination by HPLC of urinary 6-β-hydroxycortisol, an indicator of enzyme induction by rifampicin and antiepileptic drugs. Eur J Clin Pharmacol 1979;16:63-71.
23. 23. Kerb R, Brockemoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady-state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996;40:2087-93.
24. 24. Ereshefsky B, Gewertz N, Lam YW, Vega L, Ereshefsky L. Determination of SJW differential metabolism at CYP2D6 and CYP3A4, using dextromethorphan probe methodology. Presented at the Thirty-ninth Annual Meeting of the New Clinical Drug Evaluation Unit Program, Boca Raton, Florida, June 1999.
25. 25. Markowitz JS, DeVane CL, Boulton DW, Carson SW, Nahas Z, Risch SC. Effect of St John's wort (hypericum perforatum) on cytochrome P-450 2D6 and 3A4 activity in healthy volunteers. Life Sci 2000;66:133-9.
26. 26. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Canc Inst 1998;90:1225-9.
27. 27. Ball SE, Scatina J, Kao J, Feron GM, Fruncillo R, Mayer P, et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promotor region of CYP3A4. Clin Pharmacol Ther 1999;66:288-94.
28. 28. Johansson I, Yue QY, Dahl ML, Heim M, Sawe J, Bertilsson L, et al. Genetic analysis of the interethnic difference between Chinese and Caucasians in the polymorphic metabolism of debrisoquine and codeine. Eur J Clin Pharmacol 1991;40:553-6.
29. 29. Leathart JB, London SJ, Steward A, Adams JD, Idle JR, Daly AK. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogentics 1998;8:529-41.
30. 30. Kerb R, Bauer S, Brockmöller J, Roots I. Urinary 6-β-hydroxycortisol excretion rate is affected by treatment with hypericum extract [abstract]. Eur J Clin Pharmacol 1997;52(suppl):A186.
31. 31. Wrighton SA, Brian WR, Sari MA, Iwasaki M, Guengerich FP, Raucy JL, et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990;38:207-13.
32. 32. Wrighton SA, Ring BJ, Watkins PB, VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. Mol Pharmacol 1989;36:91-105.
33. 33. Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE. Morning spot and 24-hour urinary 6-β-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP 3A4 induction. J Clin Pharmacol 1999;39:487-94.
34. 34. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Marked reduction in indinavir exposure by St Johns Wort. Lancet 2000;355:547-8.
35. 35. Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000;355:548-9.
36. 36. Ernst E. Second thoughts about safety of St John' wort. Lancet 1999;354:2014-6.
37. 37. Nebel A, Schneider BJ, Baker RK, Kroll DJ. Potential metabolic interaction between St John's Wort and theophylline [letter]. Ann Pharmacother 1999;33:502.
38. 38. Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum). Clin Pharmacol Ther 1999;66:338-45.
39. 39. Maurer A, Johne A, Bauer S, Brockmöller J, Donath F, Roots I, et al. Interaction of St John's wort extract with phenprocoumn [abstract]. Eur J Clin Pharmacol 1999;55: A22.